NCT06648902View on ClinicalTrials.gov

Safety and Preliminary Efficacy of Meldonium in Patients with Metastatic Renal Cell Carcinoma and Treatment-associated Fatigue

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 1, 2022

Primary Completion Date

September 1, 2024

Study Completion Date

September 1, 2024

Conditions
Renal Cell Cancer MetastaticKidney CancerFatigue Related to Cancer Treatment
Interventions
DRUG

meldonium

500 mg (Arm A) or 1,000 mg (Arms B and C) orally daily, weeks 1-6

Trial Locations (3)

Unknown

Megis medical clinic, Tirana

National Center of Oncology, Baku

STOONCO clinic, Moscow

All Listed Sponsors
lead

Kidney Cancer Research Bureau

OTHER